BioSig invited to participate and sponsor Venice Arrhythmias 2022

BioSig Technologies, Inc.

Company to Showcase New Digital Signal Processing Technology to European EP Community at World-Class International Congress

Westport, Conn., Oct. 12, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company providing unprecedented accuracy and precision for visualization of intracardiac signals with its proprietary PURE EP™ system, announced today that she had been invited to participate in the 17th Edition Venice Arrhythmias 2022 Congress – a program sponsored by the Heart Rhythm Society taking place October 13-15, 2022 in Venice, Italy.

During the event, BioSig’s management and sales teams will present the PURE EP™ System to the European EP (electrophysiology) market for the first time. Following the recent launch of PURE EP™ Version 6 software with ACCUVIZ™ modulethe company will showcase the highly differentiated features of its digital signal processing technology, which includes advanced signal processing automation, enhanced visualization of clear cardiac signal information and TRUSOURCE™, comprehensive procedural analysis and reporting.

“It is an honor to interact with many talented physicians who are innovating in the field of electrophysiology. Their research is impacting technological advancements in the industry,” commented Kenneth L. Londoner, President and CEO of BioSig Technologies, Inc. “I couldn’t be more excited to demonstrate how the PURE EP System ™ can provide deeper clinical insights and simplify procedures. workflows to this science-based community. As a company, we celebrate their clinical legacy and embody their investment in this critical area of ​​healthcare.

About Venice Arrhythmias 2022

Venice arrhythmias 2022 is a world-renowned congress that brings together global experts and innovators in the field of cardiac arrhythmias to discuss the latest scientific advances and cutting-edge technologies in cardiac electrophysiology, pacing and clinical arrhythmia. This year’s program (17th edition) will be led by the Course Directors and Chairs of the Venice Arrhythmia Congress: Andrea Natale, MD, FHRS, Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin , Texas; Sakis Themistoclakis, MD, PhD, director of cardiology at Dell’Angelo Hospital in Venice-Mestre, Italy; and Antonio Raviele, MD, FHRS, president of the Alliance to Fight Atrial Fibrillation (ALFA).

About BioSig Technologies

BioSig-Technologies is an advanced digital signal processing technology company bringing groundbreaking insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders in the field of electrophysiology (EP), BioSig is committed to addressing top healthcare priorities: saving time, reducing costs, and saving Lives.

The Company’s First Product, the PURE EP™ System, an FDA 510(k) Class II Noninvasive Device, Provides Superior Real-Time Signal Visualization Allowing Physicians to Perform Cardiac Ablation Procedures highly targeted and insight-based with increased procedural efficiency and effectiveness.

The PURE EP™ System is currently undergoing a nationwide commercial launch and is an integral part of reputable healthcare systems, such as the Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute. In a blind clinical study recently published in the Journal of Cardiovascular Electrophysiology, electrophysiologists rated PURE EP™ as equivalent or superior to conventional systems in 93.6% of signal samples, with 75.2% scoring higher.

The global EP market is expected to reach $16 billion in 2028 with a growth rate of 11.2%.1

Forward-looking statements

This press release contains “forward-looking statements”. Such statements may be preceded by the words “intends”, “may”, “will”, “plans”, “expects”, “anticipates”, “projects”, “predicts”, “estimates”. , “aim”, “believe”. ‘, ‘hope’, ‘potential’ or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company and cannot be predicted or quantified and, therefore, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with (i) market conditions and the Company’s intended use of the products, (ii) the geographic, social and economic impact of COVID -19 our ability to conduct our business and raise capital in the future if needed, (iii) our inability to manufacture our products and product candidates on a commercial scale by ourselves or in collaboration with third parties; (iv) difficulties in obtaining financing on commercially reasonable terms; (v) changes in the size and nature of our competitors; (vi) the loss of one or more key executives or scientists; and (vii) difficulties obtaining regulatory approval to commercialize our products and product candidates. More detailed information about the company and the risk factors that may affect the making of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission (SEC), including the company’s annual report on Form 10. -K and its Quarterly Report Reports on Form 10-Q. Investors and security holders are urged to read these materials free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

1 Global Market Insights Inc. March 8, 2022.

CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 55 Greens Farms Road, 1st Floor Westport, CT 06880 [email protected] 203-409-5444, x133

#BioSig #invited #participate #sponsor #Venice #Arrhythmias

Related Articles

Back to top button